Abstract
Human herpesvirus 8 (HHV-8) encodes a viral FLICE inhibitory protein (vFLIP), called K13, with homology to the prodomain of caspase 8. K13 has been postulated to protect virally infected cells against death receptor-induced apoptosis. We report that K13 leads to constitutive upregulation of IL-8 secretion by transcriptional upregulation of its promoter. K13-induced IL-8 promoter activation is dependent on an intact NF-κB-binding site and is associated with increased binding of classical NF-κB pathway subunits p65, c-Rel and p50, respectively. IL-8 production is defective in K13 mutants defective in classical NF-κB activation and is blocked by genetic and pharmacological inhibitors of this pathway. In contrast, K13 failed to activate the JNK/AP-1 pathway and deletion of AP-1-binding site in the IL-8 promoter or use of a specific JNK inhibitor had only a partial effect on K13-induced IL-8 promoter activation. Collectively, above results demonstrate that K13 is a major mediator of IL-8 production and therapeutic agents targeting K13-induced NF-κB pathway may have a role in the treatment of conditions in which HHV-8-induced IL-8 production plays a pathogenic role.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Adams J, Elliott PJ . (2000). Oncogene 19: 6687–6692.
An J, Sun Y, Sun R, Rettig MB . (2003). Oncogene 22: 3371–3385.
Bais C, Van Geelen A, Eroles P, Mutlu A, Chiozzini C, Dias S et al. (2003). Cancer Cell 3: 131–143.
Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W et al. (2001). Proc Natl Acad Sci USA 98: 13681–13686.
Bertin J, Armstrong RC, Ottilie S, Martin DA, Wang Y, Banks S et al. (1997). Proc Natl Acad Sci USA 94: 1172–1176.
Chaudhary PM, Eby MT, Jasmin A, Hood L . (1999a). J Biol Chem 274: 19211–19219.
Chaudhary PM, Jasmin A, Eby MT, Hood L . (1999b). Oncogene 18: 5738–5746.
Dourmishev LA, Dourmishev AL, Palmeri D, Schwartz RA, Lukac DM . (2003). Microbiol Mol Biol Rev 67: 175–212.
Ensoli B, Gallo RC . (1995). Proc Assoc Am Physicians 107: 8–18.
Falvo JV, Parekh BS, Lin CH, Fraenkel E, Maniatis T . (2000). Mol Cell Biol 20: 4814–4825.
Gershengorn MC, Geras-Raaka E, Varma A, Clark-Lewis I . (1998). J Clin Invest 102: 1469–1472.
Hoffmann E, Dittrich-Breiholz O, Holtmann H, Kracht M . (2002). J Leukoc Biol 72: 847–855.
Holtmann H, Winzen R, Holland P, Eickemeier S, Hoffmann E, Wallach D et al. (1999). Mol Cell Biol 19: 6742–6753.
Hu S, Vincenz C, Buller M, Dixit VM . (1997). J Biol Chem 272: 9621–9624.
Jiang G, Dallas-Yang Q, Liu F, Moller DE, Zhang BB . (2003). J Biol Chem 278: 180–186.
Kapahi P, Takahashi T, Natoli G, Adams SR, Chen Y, Tsien RY et al. (2000). J Biol Chem 275: 36062–36066.
Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM et al. (1992). Science 258: 1798–1801.
Lane BR, Liu J, Bock PJ, Schols D, Coffey MJ, Strieter RM et al. (2002). J Virol 76: 11570–11583.
Lane BR, Lore K, Bock PJ, Andersson J, Coffey MJ, Strieter RM et al. (2001). J Virol 75: 8195–8202.
Le X, Shi Q, Wang B, Xiong Q, Qian C, Peng Z et al. (2000). J Interferon Cytokine Res 20: 935–946.
Li Q, Lu Q, Hwang JY, Buscher D, Lee KF, Izpisua-Belmonte JC et al. (1999a). Genes Dev 13: 1322–1328.
Li Q, Van Antwerp D, Mercurio F, Lee KF, Verma IM . (1999b). Science 284: 321–325.
Liu L, Eby MT, Rathore N, Sinha SK, Kumar A, Chaudhary PM . (2002). J Biol Chem 277: 13745–13751.
Makris C, Godfrey VL, Krahn-Senftleben G, Takahashi T, Roberts JL, Schwarz T et al. (2000). Mol Cell 5: 969–979.
Masood R, Cai J, Law R, Gill P . (1993). Curr Opin Oncol 5: 831–834.
Masood R, Cai J, Tulpule A, Zheng T, Hamilton A, Sharma S et al. (2001). Clin Cancer Res 7: 2693–2702.
Matta H, Chaudhary PM . (2004). Proc Natl Acad Sci USA 101: 9399–9404.
Matta H, Sun Q, Moses G, Chaudhary PM . (2003). J Biol Chem 278: 52406–52411.
Moore PS, Chang Y . (2003). Annu Rev Microbiol 57: 609–639.
Mori N, Mukaida N, Ballard DW, Matsushima K, Yamamoto N . (1998). Cancer Res 58: 3993–4000.
Mukaida N, Morita M, Ishikawa Y, Rice N, Okamoto S, Kasahara T et al. (1994). J Biol Chem 269: 13289–13295.
Nurnberg W, Tobias D, Otto F, Henz BM, Schadendorf D . (1999). J Pathol 189: 546–551.
Pear WS, Miller JP, Xu L, Pui JC, Soffer B, Quackenbush RC et al. (1998). Blood 92: 3780–3792.
Pomerantz JL, Baltimore D . (2002). Mol Cell 10: 693–695.
Roussel RR, Barchowsky A . (2000). Arch Biochem Biophys 377: 204–212.
Sarid R, Flore O, Bohenzky RA, Chang Y, Moore PS . (1998). J Virol 72: 1005–1012.
Schulz TF . (1998). J Gen Virol 79: 1573–1591.
Singh RK, Varney ML, Bucana CD, Johansson SL . (1999). Melanoma Res 9: 383–387.
Sinha SK, Chaudhary PM . (2004). J Biol Chem 279: 41873–41881.
Sinha SK, Zachariah S, Quinones HI, Shindo M, Chaudhary PM . (2002). J Biol Chem 277: 44953–44961.
Smith DR, Polverini PJ, Kunkel SL, Orringer MB, Whyte RI, Burdick MD . (1994). J Exp Med 179: 1409–1415.
Sparmann A, Bar-Sagi D . (2004). Cancer Cell 6: 447–458.
Sturzl M, Hohenadl C, Zietz C, Castanos-Velez E, Wunderlich A, Ascherl G et al. (1999). J Natl Cancer Inst 91: 1725–1733.
Sun Q, Matta H, Chaudhary PM . (2005). Retrovirology 2: 9.
Sun Q, Zachariah S, Chaudhary PM . (2003). J Biol Chem 278: 52437–52445.
Thome M, Schneider P, Hofmann K, Fickenscher H, Meinl E, Neipel F et al. (1997). Nature 386: 517–521.
Ueda T, Shimada E, Urakawa T . (1994). J Gastroenterol 29: 423–429.
Verma SC, Robertson ES . (2003). FEMS Microbiol Lett 222: 155–163.
Wang JF, Liu ZY, Anand AR, Zhang X, Brown LF, Dezube BJ et al. (2004). Biochim Biophys Acta 1691: 129–139.
Watanabe K, Kinoshita S, Nakagawa H . (1989). Biochem Biophys Res Commun 161: 1093–1099.
Wu GD, Lai EJ, Huang N, Wen X . (1997). J Biol Chem 272: 2396–2403.
Yang TY, Chen SC, Leach MW, Manfra D, Homey B, Wiekowski M et al. (2000). J Exp Med 191: 445–454.
Yokoe T, Iino Y, Takei H, Horiguchi J, Koibuchi Y, Maemura M et al. (1997). Anticancer Res 17: 695–699.
Acknowledgements
We thank Dr Andrew Keates for the IL-8 reporter constructs and Drs Inder Verma, Michael Karin and Richard Gaynor for the IKKs-deficient MEF cells. This work was supported by a grant from the National Institutes of Health (R01 CA85177) and the Mario Lemieux Foundation.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sun, Q., Matta, H., Lu, G. et al. Induction of IL-8 expression by human herpesvirus 8 encoded vFLIP K13 via NF-κB activation. Oncogene 25, 2717–2726 (2006). https://doi.org/10.1038/sj.onc.1209298
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1209298
Keywords
This article is cited by
-
Latent infection with Kaposi’s sarcoma-associated herpesvirus enhances retrotransposition of long interspersed element-1
Oncogene (2019)
-
COX-2/PGE2: molecular ambassadors of Kaposi's sarcoma-associated herpes virus oncoprotein-v-FLIP
Oncogenesis (2012)
-
Transcriptional profiling of host gene expression in chicken embryo lung cells infected with laryngotracheitis virus
BMC Genomics (2010)
-
Kaposi's sarcoma and its associated herpesvirus
Nature Reviews Cancer (2010)
-
Kaposi's sarcoma-associated herpesvirus-encoded viral FLICE inhibitory protein (vFLIP) K13 suppresses CXCR4 expression by upregulating miR-146a
Oncogene (2010)
